CytomX Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
CytomX Therapeutics (CTMX) IPO Opens Sharply Higher, Pares Gains
October 8, 2015 2:49 PM EDTToday's IPO for CytomX Therapeutics, Inc. (NASDAQ: CTMX) opened for trading earlier at $16 after pricing 6,666,667 shares of common stock at an initial public offering price of $12 per share, below the $14-$16 range. Shares have since backed down to $14.35.
In addition, the underwriters have a 30-day option to purchase up to an additional 1,000,000 shares of common stock from CytomX. All shares of common stock are being offered by CytomX.
BofA Merrill Lynch, Jefferies LLC and Cowen and... More
CytomX Therapeutics (CTMX) IPO Prices at $12, Below Expected Range
October 8, 2015 8:51 AM EDTCytomX Therapeutics, Inc. (NASDAQ: CTMX) announced the pricing of its initial public offering of 6,666,667 shares of common stock at an initial public offering price of $12 per share, below the $14-$16 range. The shares are expected to begin trading on the NASDAQ Global Select Market today under the ticker symbol "CTMX."
In addition, the underwriters have a 30-day option to purchase up to an additional 1,000,000 shares of common stock from CytomX. All shares of common stock are being offered by CytomX.... More
